Liposomal amphotericin B (L-AMB) as initial therapy for invasive filamentous fungal infections (IFFI): A randomized, prospective trial of a high loading regimen vs. standard dosing (AmBiLoad trial).

被引：0
|
作者：
Cornely, OA
Maertens, J
Bresnik, M
Herbrecht, R
机构：
[1] Univ Cologne, Dept Internal Med, Cologne, Germany
[2] Univ Hosp Gasthuisberg, Dept Hematol, B-3000 Louvain, Belgium
[3] Gilead Sci Inc, Foster City, CA 94404 USA
[4] Hop Hautepierre, Dept Hematol & Oncol, Strasbourg, France
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3222
引用
收藏
页码：900A / 900A
页数：1
相关论文
共 7 条
  • [1] Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)
    Cornely, Oliver A.
    Maertens, Johan
    Bresnik, Mark
    Ebrahimi, Ramin
    Ullmann, Andrew J.
    Bouza, Emilio
    Heussel, Claus Peter
    Lortholary, Olivier
    Rieger, Christina
    Boehme, Angelika
    Aoun, Mickael
    Horst, Heinz-August
    Thiebaut, Anne
    Ruhnke, Markus
    Reichert, Dietmar
    Vianelli, Nicola
    Krause, Stefan W.
    Olavarria, Eduardo
    Herbrecht, Raoul
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 44 (10) : 1289 - 1297
  • [2] Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)
    Fortun Abete, Jesus
    [J]. REVISTA ESPANOLA DE QUIMIOTERAPIA, 2016, 29 : 13 - 16
  • [3] Standard dosing regimen of liposomal amphotericin B is as effective as a high-loading dose for patients with invasive aspergillosis:: AmBiLoad trial
    Loss-Floerl, Cornelia
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2007, 5 (06) : 929 - 932
  • [4] A randomized phase III trial of low dose liposomal amphotericin B (L-AmB) as prophylaxis of invasive fungal infections (IFI) in neutropenic patients (pts).
    Penack, O
    Schwartz, S
    Martus, P
    Reinwald, M
    Schmidt-Hieber, M
    Thiel, E
    Blau, IW
    [J]. BLOOD, 2005, 106 (11) : 28A - 28A
  • [5] Efficacy outcomes in a randomized trial of liposomal amphotericin B (L-AMB) based on Revised EORTC/MSG 2008 definitions of invasive fungal disease (IFD)
    Cornely, O. A.
    Maertens, J.
    Bresnik, M.
    Ebrahimi, R.
    Dellow, E.
    Herbrecht, R.
    Donnelly, P. J.
    [J]. MYCOSES, 2009, 52 : 83 - 83
  • [6] Liposomal amphotericin B (L-AMB) is superior to amphotericin B deoxycholate (AmB-d) in preventing breakthrough fungal infections in patients with prolonged neutropenia and fever: Results of a sub-group analysis of an empirical antifungal therapy trial.
    Cordonnier, C
    Walsh, TJ
    Bresnik, M
    [J]. BLOOD, 2004, 104 (11) : 376A - 376A
  • [7] Posaconazole vs standard azole (FLU/ITRA) therapy for prophylaxis of invasive fungal infections (IFIs) among high-risk neutropenic patients: Results of a randomized, multicenter trial.
    Cornely, O
    Maertens, J
    Winston, D
    Perfect, J
    Helfgott, D
    Ullmann, A
    Holowiecki, J
    Stockelberg, D
    Goh, YT
    Petrini, M
    Walsh, T
    Gogate, J
    Hardalo, C
    Angulo-Gonzalez, D
    [J]. BLOOD, 2005, 106 (11) : 524A - 524A
1